Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour FEV1 crossover study of BI 1744 CL versus tiotropium in COPD
2009-014418-86Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olodaterol and tiotropium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Forced expiratory volume in one second and 24-hour FEV1-time profile of BI 1744 CL. Started Oct 2009; status: completed.
02
Drugs
olodateroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-014418-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014418-86.